Catalyst Pharmaceuticals (CPRX) Reports Record Q4 and Full Year 2025 Results

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is one of the best cheap biotech stocks to buy now. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) reported record fiscal Q4 and record full year 2025 financial results on February 25. Total revenues for the full year 2025 came up to $589.0 million, reflecting a 19.8% year-over-year growth and marking another year of record total revenues for the company. Total revenues for fiscal Q4 2025 were $152.6 million, supported by an 18.3% FIRDAPSE® growth and 67.5% growth of AGAMREE®, which shows continued adoption.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) expects total revenues for the full year 2026 to be in the $615 million and $645 million range, which, according to management, shows confidence in the strength and durability of the FIRDAPSE and AGAMREE franchises. The company attributed strong fiscal Q4 2025 performance to the ongoing organic product growth and the accelerating market uptake of AGAMREE, while the solid full-year 2025 performance was supported by sustained organic momentum and operational discipline.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a commercial-stage, biopharmaceutical company involved in the development, in-licensing, and commercialization of novel medicines for patients with difficult-to-treat and rare diseases.

While we acknowledge the potential of CPRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.